Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.70 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | SNCA | P37840 | 1/20 | 0.65 |
| ▸ | STAT3 | P40763 | 1/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.60 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.60 |
| ▸ | PIP4K2C | Q8TBX8 | 3/20 | 0.59 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20919982 | 1.00 | CRBN (0.70) | CRBNDDB1HDAC1HDAC6HDAC3 | |
| SCHEMBL17873780 | 1.00 | CRBN (0.70) | CRBNDDB1HDAC1HDAC6HDAC3 | |
| SCHEMBL23884363 | 0.99 | CRBN (0.71) | CRBNDDB1HDAC1HDAC6HDAC3 | |
| SCHEMBL26319140 | 0.97 | CRBN (0.72) | CRBNDDB1HDAC1HDAC6HDAC3 | |
| SCHEMBL26317549 | 0.97 | CRBN (0.72) | CRBNDDB1HDAC1HDAC6HDAC3 | |
| SCHEMBL17839764 | 0.96 | CRBN (0.69) | CRBNDDB1HDAC1HDAC6HDAC3 | |
| SCHEMBL26317544 | 0.96 | CRBN (0.73) | CRBNDDB1HDAC1HDAC6HDAC3 | |
| SCHEMBL17873761 | 0.95 | CRBN (0.70) | CRBNDDB1HDAC1HDAC6HDAC3 | |
| SCHEMBL29558168 | 0.94 | CRBN (0.74) | CRBNDDB1HDAC1HDAC6HDAC3 | |
| SCHEMBL24418639 | 0.94 | CRBN (0.74) | CRBNDDB1HDAC1HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002360-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2024-01-04 | — | — | US | disclosed |
| US-20230406859-A1 | METHOTREXATE ANALOGS AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-12-21 | — | — | US | disclosed |
| US-11787778-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | MONTELINO THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20210292298-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2021-09-23 | — | — | US | disclosed |
| US-20200239430-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | MONTELINO THERAPEUTICS, LLC (US) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406859-A1 | METHOTREXATE ANALOGS AND METHODS OF USE | MTX1, MTX2, MGMT | CRBN 4131/4885DDB1 1682/4885HDAC1 1031/4885 |
| US-11787778-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | AR, ADRM1, PSMA3 | CRBN 256/4885DDB1 2125/4885HDAC1 508/4885 |
| US-20200239430-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | CRBN 235/4885DDB1 2244/4885HDAC1 468/4885 |
| US-20240002360-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | CRBN 235/4885DDB1 2244/4885HDAC1 468/4885 |
| US-20210292298-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | CRBN 235/4885DDB1 2244/4885HDAC1 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.